Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.

Cancer science - 1 Sept 2011

Kondo Norio, Tsukuda Mamoru, Taguchi Takahide, Nakazaki Kouichi, Sakakibara Atsuko, Takahashi Hideaki, Toth Gabor, Nishimura Goshi

Abstract excerpt

Cetuximab is a chimeric IgG1 monoclonal antibody that targets epidermal growth factor receptor (EGFR). Cetuximab binds to EGFR and prevents phosphorylation of EGFR. Moreover, preclinical results have shown the ability of cetuximab to induce either complement-mediated tumor cell killing (CDC) or antibody-dependent cell-mediated-cytotoxicity (ADCC). We previously reported mutation in EGFR regarding head and neck...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Class I Phosphatidylinositol 3-Kinases

Share to Head and Neck Neoplasms

Share to Neoplasms, Squamous Cell

Share to PTEN Phosphohydrolase

Share to Squamous Cell Carcinoma of Head and Neck

Source

Identifiers

PMID: 21631644
DOI: 10.1111/j.1349-7006.2011.01999.x

Genes

EGFR
BRAF
KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.PMID 21631644Read ↗

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.Semantic proximity Read ↗

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.Semantic proximity Read ↗

Effect of cetuximab treatment in squamous cell carcinomas.Semantic proximity Read ↗

Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.Semantic proximity Read ↗

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.Semantic proximity Read ↗

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.Semantic proximity Read ↗

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.Semantic proximity Read ↗

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.Semantic proximity Read ↗

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.Semantic proximity Read ↗

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.